Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(der the Plavix(R) and Avapro(R) alliance...),Health

Minority interests came to euro 419 million, compared with euro 393 million in 2006. This line includes the share of pre-tax profits paid to BMS from territories managed by sanofi-aventis (euro 403 million, versus euro 375 million in 2006).

Adjusted net income rose by 1.0% to euro 7,110 million, while adjusted earnings per share (adjusted EPS) was euro 5.28 (1.0% higher than the 2006 figure of euro 5.23), based on an average number of shares outstanding of 1,346.9 million in 2007 and 1,346.8 million in 2006.

Excluding selected items (see Appendix 5), adjusted net income was euro 6,961 million (up 5.9% on the 2006 figure of euro 6,571 million), and adjusted EPS was euro 5.17 (up 5.9% on the 2006 figure of euro 4.88).

Expressed in U.S. dollars(2) and excluding selected items, adjusted net income was $9,544 million (up 15.6% on the 2006 figure) and adjusted EPS was $7.09 (up 15.7% on the 2006 figure).

(2) U.S. dollar figures obtained by translating euro-denominated figures at the average exchange rate for the period: 1.449 for Q4 2007 (1.290 for Q4 2006) and 1.371 for FY 2007 (1.256 for FY 2006)

2007 consolidated statement of cash flow and balance sheet at December 31, 2007

Operating cash flow before changes in working capital was euro 7,917 million, compared with euro 7,610 million in 2006.

Working capital needs increased by euro 811 million, compared with euro 1,006 million in 2006.

Investing activities generated a net cash outflow of euro 1,716 million over the period.

Acquisitions of property, plant and equipment and intangibles amounted to euro 1,610 million, essentially comprising investment in industrial plant and equipment and contractual payments for intangible rights. These acquisitions of intangible rights (euro 231 million in 2007) mainly c
'/>"/>